Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/65770
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRuiz-Delgado, G.J.
dc.contributor.authorGomez-Almaguer, D.
dc.contributor.authorTarin-Arzaga, L.C.
dc.contributor.authorCantu-Rodriguez, O.G.
dc.contributor.authorUrdaneta, C.A.
dc.contributor.authorRodriguez-Morales, U.
dc.contributor.authorCalderon-Garcia, J.
dc.contributor.authorFernandez-Vargas, O.
dc.contributor.authorMontes-Montiel, M.
dc.contributor.authorSanchez-Cardenas, M.
dc.contributor.authorRuiz-Arguelles, G.J.
dc.date.accessioned2015-11-19T18:50:41Z-
dc.date.available2015-11-19T18:50:41Z-
dc.date.issued2012
dc.identifier.urihttp://hdl.handle.net/20.500.12104/65770-
dc.description.abstractRituximab (R) has changed the prognosis of patients with non-Hodgkin's lymphoma (NHL) in developed countries, but its role has not been analyzed in underprivileged circumstances. One hundred and two patients with NHL treated in a developing country were analyzed: 28 patients with follicular lymphoma (FL) and 74 with diffuse large B-cell lymphoma (DLCL). Patients were treated upfront with either cyclo- phosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP; the decision to employ R depending solely on the ability of patients to defray it. In DLCL, 42 were given CHOP and 32 R-CHOP, whereas in FL, 19 were given CHOP and 9 R-CHOP. The impact of the addition of R was found to be clearer in FL than in DLCL. In patients with DLCL, the overall survival (OS) was 87% at 80 months for those treated with R-CHOP and 84% at 145 months for those treated with CHOP (not significant). In patients with FL, the OS was 89% at 88 months for those treated with R-CHOP and 71% at 92 months for those treated with CHOP (P50.05). In a multivariate analysis, other variables which were identified to be associated with the OS were IPI and number of cycles in DLCL. It is concluded that R produced a mild positive impact in the OS of patients with FL, but not in those with DLCL. Since the addition of R results in a 36-fold increase in treatment costs, these observations may be important to decide therapeutic approaches in NHL patients living in underprivileged circumstances. © W. S. Maney & Son Ltd 2012.
dc.titleIs there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?
dc.typeArticle
dc.identifier.doi10.1179/1607845412Y.0000000006
dc.relation.ispartofjournalHematology
dc.relation.ispartofvolume17
dc.relation.ispartofissue4
dc.relation.ispartofpage193
dc.relation.ispartofpage197
dc.subject.keywordCHOP; Lymphoma; Non-hodgkin; Prognosis; R-CHOP; Rituximab; Treatment
dc.contributor.affiliationRuiz-Delgado, G.J., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico, Laboratorios Clínicos de Puebla, Clínica RUIZ, Mexico, Universidad Popular Autónoma del Estado de Puebla, Mexico; Gómez-Almaguer, D., Hospital Universitario de Nuevo León, Mexico; Tarín-Arzaga, L.C., Hospital Universitario de Nuevo León, Mexico; Cantú-Rodriguez, O.G., Hospital Universitario de Nuevo León, Mexico; Urdaneta, C.A., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico, Benemérita Universidad Autónoma de Puebla, Mexico; Rodríguez-Morales, U., Universidad Popular Autónoma del Estado de Puebla, Mexico; Calderón-Garcia, J., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico, Facultad de Medicina, Universidad La Salle, Mexico; Fernández-Vargas, O., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico; Montes-Montiel, M., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico; Sánchez-Cárdenas, M., Hospital Universitario de Nuevo León, Mexico; Ruiz-Argüelles, G.J., Centro de Hematología y Medicina Interna, Clínica RUIZ, Puebla, Mexico, Laboratorios Clínicos de Puebla, Clínica RUIZ, Mexico, Universidad Popular Autónoma del Estado de Puebla, Mexico
dc.relation.isReferencedByScopus
dc.relation.isReferencedByWOS
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84866128851&partnerID=40&md5=24005ac7d57282ac68f0d83b75d97168
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.